Clinical UM Guideline
|Subject:||Tropism Testing for HIV Management|
|Guideline #:||CG-LAB-03||Current Effective Date:||06/28/2016|
|Status:||Reviewed||Last Review Date:||05/05/2016|
This document addresses the use of phenotypic coreceptor tropism assay tests in the management of individuals with human immunodeficiency virus type-1 (HIV-1) infection. Phenotypic coreceptor tropism testing with the Trofile® assay (Trofile or Trofile DNA, Monogram Biosciences, Inc., South San Francisco, CA) is performed to identify HIV viral tropism (that is, chemokine receptor 5 [CCR5], chemokine receptor 4 [CXCR4], or dual/mixed-tropic) to assist in selection of individuals for a CCR5 antagonist.
HIV tropism testing with a phenotypic coreceptor tropism assay is considered medically necessary in an HIV-1 infected individual for either of the following indications:
Not Medically Necessary:
HIV tropism testing with a phenotypic coreceptor tropism assay is considered not medically necessary for all other indications, including, but not limited to the following:
The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.
|87999||Unlisted microbiology procedure [when specified as HIV tropism testing with a phenotypic coreceptor tropism assay]|
|B20||Human immunodeficiency virus [HIV] disease|
|O98.711||Human immunodeficiency [HIV] disease complicating pregnancy, first trimester|
|O98.712||Human immunodeficiency [HIV] disease complicating pregnancy, second trimester|
|O98.713||Human immunodeficiency [HIV] disease complicating pregnancy, third trimester|
|O98.719||Human immunodeficiency [HIV] disease complicating pregnancy, unspecified trimester|
|O98.72||Human immunodeficiency [HIV] disease complicating childbirth|
|O98.73||Human immunodeficiency [HIV] disease complicating the puerperium|
|Z21||Asymptomatic human immunodeficiency virus [HIV] infection status|
|Z71.7||Human immunodeficiency virus [HIV] counseling|
HIV enters cells by a complex process that involves attachment to the CD4 receptor followed by binding to either the CCR5 or CXCR4 molecules and fusion of the viral and cell membranes. The CCR5 coreceptor antagonist (inhibitor) antiretroviral drug, maraviroc (Selzentry®, ViiV Healthcare, Research Triangle Park, NC; Pfizer Manufacturing Deutschland GmbH), prevents HIV entry into target cells by binding to the CCR5 receptor. To date, Selzentry is the only U.S. Food and Drug Administration (FDA) approved CCR5 antagonist agent available to treat CCR5-tropic HIV-1 infection.
The HIV-1 infection, which causes acquired immunodeficiency syndrome (AIDS), uses coreceptor proteins (either CCR5 or CXCR4) on the surface of target cells to enter and infect the cells. The most commonly transmitted strains of HIV-1 bind to CCR5 and are said to have "tropism" for CCR5-expressing cells. Over the course of infection, CXCR4 using HIV-1 clones emerge in some infected individuals. Viruses in many untreated individuals eventually exhibit a shift in coreceptor tropism from CCR5 to either CXCR4 or both CCR5 and CXCR4 (that is, dual- or mixed-tropic; D/M tropic). This shift is temporally associated with a more rapid decline in CD4 T-cell counts (DHHS, 2016). Coreceptor antagonists have been designed to interfere with the interaction between HIV-1 and its coreceptors.
The International Antiviral Society-USA Panel (Günthard, 2014) updated recommendations for initial antiretroviral therapy (ART) and multi-drug resistant adult HIV-1 infection state:
Initial ART, selected based on baseline resistance testing and patient characteristics and preference, continues to be based on a combination of 2 nucleoside reverse transcriptase inhibitors (NRTIs) and a third agent, either an INSTI [Integrase Strand Transfer Inhibitor], a nonnucleoside reverse transcriptase inhibitor (NNRTI), or a boosted protease inhibitor (PI)… ART drugs typically used with a boosted PI in regimens for multidrug-resistant HIV include etravirine, dolutegravir, maraviroc, and in exceptional circumstances the fusion inhibitor enfuvirtide.
Maraviroc is the first, and currently the only chemokine coreceptor antagonist drug approved by the FDA to treat CCR5-tropic HIV-1. Maraviroc is a selective, slowly reversible, small-molecule antagonist of the interaction between human cell surface CCR5 and HIV-1 glycoprotein 120 (gp120), necessary for HIV-1 cell infection. Blocking this interaction prevents CCR5-using HIV-1 strains from entry into cells. However, CXCR4-using HIV-1 strains are not prevented. On November 20, 2009, the FDA approved a supplemental new drug application (NDA) to expand the indication for maraviroc to include combination antiretroviral treatment of therapy-naïve adults infected with CCR5-tropic HIV-1 virus. The expanded indication is based on safety and efficacy data collected through 96 weeks from the large, double-blind, prospective randomized MERIT trial (Maraviroc versus Efavirenz in Treatment-Naive Patients) which compared combination therapy of maraviroc/zidovudine/lamivudine to the combination therapy regimen of efavirenz/zidovudine/lamivudine (Cooper, 2010; Saag, 2009). In treatment-naive subjects, more subjects treated with maraviroc experienced virologic failure and developed lamivudine resistance compared with efavirenz. Presently, there is no data available in the pediatric population; therefore, maraviroc should not be used in individuals younger than 16 years of age (Selzentry Product Information [PI], 2015).
For the clinical studies of individuals with treatment failure, tropism at enrollment and again at baseline was determined using the original phenotypic Trofile assay for 2560 potential enrollees; 56% were CCR5-tropic only and were eligible for the clinical trials. Most other individuals had dual/mixed coreceptor protein HIV infection; CXCR4-infection alone is rare. Of the individuals enrolled, 90% had CCR5-tropic virus at baseline, 4% had dual/mixed tropic virus, and 5% had non-typable virus infection.
Based on information presented to the FDA Antiviral Drugs Advisory Committee and on published assay validation data (Whitcomb, 2007), the original phenotypic Trofile assay had a turnaround time of 14 to 18 days, failed to work in 3%-7% of individuals, and required at least 1,000 copies/mL of HIV RNA. The assay was 100% effective in detecting model CXCR4-tropic or dual/mixed HIV present in a 10% mixture, and 83% effective at a 5% mixture. Validation studies also indicated 100% accuracy of results for 38 samples with known tropism, and 100% reproducibility including repeat assays using multiple operators, instrumentation, reagent lots, and conducted over a 14-day period. No false-positive results were obtained on samples that were HIV-negative but positive for either hepatitis B or C virus.
A more sensitive, second-generation assay replaced the original Trofile assay. The assay examines the complete gp160 coding region of the HIV-1 envelope protein. According to information from Monogram Biosciences, the enhanced sensitivity Trofile can detect CXCR4-tropic virus present at levels less than 0.3% of the total virus population, and at that level of virus, the assay is 100% sensitive. Viral load must be at least 1,000 copies/ml to determine viral tropism. Supportive data, however, have not yet been published. No information could be found on turnaround time; it is assumed to be unchanged from the original assay, that is, 14-18 days.
The enhanced sensitivity Trofile assay became available after week 48 analysis of the phase III treatment-naïve MERIT trial (Maraviroc versus Efavirenz in Treatment-Naïve Patients); approximately 15% of the subjects identified as CCR5-tropic using the original assay had dual/mixed- or CXCR4-tropic virus by the enhanced sensitivity assay. Reanalysis of the data at week 96 of the MERIT study using the enhanced sensitivity assay screening results reduced the number of maraviroc virologic failures with dual/mixed- or CXCR4-tropic virus to 12 compared to 24 of the 311 subjects when screening with the original Trofile HIV tropism assay (Selzentry PI, 2015).
Based on the clinical studies used for the FDA approval, and the labeled requirement for tropism testing prior to initiating a course of maraviroc, HIV tropism testing using the Trofile assay is recommended for both treatment-experienced and treatment-naïve individuals who are being considered for immediate treatment with maraviroc. Because maraviroc requires twice-daily dosing and requires a tropism assay prior to use, the DHHS guideline (2015) no longer recommends maraviroc for use as initial therapy, "given that many better options are now available…and maraviroc has no virologic benefit when compared with other recommended regimens."
Phenotypic assays are used most often in the clinical trials of CCR5 antagonists, and are considered the "gold standard" for comparison with other methods of tropism testing. Enhancements have allowed detection of a lower threshold of minor CXCR4-using species (Lin, 2009). The Trofile DNA assay test is commercially available to determine the coreceptor tropism (CCR5, CXCR4, or dual/mixed) status of the HIV-1 strain when an individual's HIV-1 viral load is less than 1,000 copies/mL. The Trofile DNA is a single cycle pseudovirion-based tropism assay that uses the complete gp160 coding region of the HIV-1 virus to evaluate tropism. Instead of using HIV RNA isolated from an individual's plasma as in the Trofile assay, the Trofile DNA assay uses cell associated viral DNA taken from whole blood cells infected with HIV. The turnaround time is unchanged from the original assay (that is, 14-18 days). Testing is by polymerase chain reaction (PCR) amplification and viral culture.
The U.S. Department of Health and Human Services Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents (DHHS, 2016) recommends the use of coreceptor tropism assays in clinical practice as follows:
In addition, the DHHS guidelines state:
A tropism assay may potentially be used in clinical practice for prognostic purposes or to assess tropism before starting ART if future use of a CCR5 antagonist is anticipated (e.g., a regimen change for toxicity). Currently, sufficient data do not exist to support these uses.
The Antiretroviral Treatment of Adult HIV Infection - 2014 Recommendations of the International Antiviral Society-USA Panel (Günthard, 2014) state:
If maraviroc is being considered, tropism should be determined because maraviroc is only active against exclusively CCR5-tropic virus. If CXCR4 or dual-mixed tropism is present, maraviroc is not suitable.
Acquired Immunodeficiency Syndrome (AIDS): A disease of the body's immune system caused by the human immunodeficiency virus (HIV). AIDS is characterized by the death of CD4 cells (an important part of the body's immune system), which leaves the body vulnerable to life-threatening conditions, such as infections and cancers.
Antagonist: Block the binding of an agonist (a substance that binds to a specific receptor and triggers a response in the cell) at a receptor site. Coreceptor antagonists prevent the HIV virus from attaching to CD4 coreceptor.
CD4 cells: A type of infection-fighting white blood cell that carries the CD4 receptor on its surface; also known as helper T cell or CD4 lymphocyte. CD4 cells coordinate the immune response, which signals other cells in the immune system to perform their special functions. The number of CD4 cells in a sample of blood is an indicator of the health of the immune system. HIV infects and kills CD4 cells, which leads to a weakened immune system.
Chemokine receptor 5 (CCR5): A protein on the surface of some immune system cells. Along with CXCR4, it is one of two coreceptors that HIV can use along with the CD4 receptor to bind to and enter host cells.
Coreceptor: A protein on the surface of a cell that serves as a second binding site for a virus or other molecule. Although the CD4 protein is HIV's primary receptor, the virus must also bind to either the CCR5 or CXCR4 coreceptor to get into a host cell.
Human Immunodeficiency Virus (HIV): The virus that causes Acquired Immunodeficiency Syndrome (AIDS). HIV is in the retrovirus family and is responsible for most HIV infections throughout the world.
Treatment-experienced: A term used to describe HIV-infected individuals who are currently being treated with anti-HIV drugs or who have taken anti-HIV drugs in the past.
Treatment failure: A broad term that describes failure of an anti-HIV treatment to adequately control HIV infection. The three types of HIV treatment failure are virologic, immunologic, and clinical failure. Factors that contribute to treatment failure include poor adherence, drug resistance, and drug toxicity.
Treatment-naïve: A term used to describe HIV-infected individuals who have never taken anti-HIV drugs.
Viral load (VL): The amount of HIV RNA in a blood sample, reported as number of HIV RNA copies per milliliter of blood plasma; also known as HIV RNA. The VL provides information about the number of cells infected with HIV and is an important indicator of HIV progression and of how well treatment is working.
Viral tropism: Refers to which type of coreceptor HIV uses when binding to a cell during infection. HIV can bind to the CXCR4 coreceptor (X4-tropic) or to the CCR5 coreceptor (R5-tropic) on a cell surface. Although the virus often prefers one coreceptor to the other, it also can be dual/mixed-tropic HIV that can bind to either coreceptor. Viral tropism may switch, or change from preference of one coreceptor to the other, during the course of an HIV infection.
Virologic failure: The inability of anti-HIV drug treatment to reduce viral load or to maintain suppression of viral load. Virologic failure is the most common type of treatment failure and may lead to immunologic and clinical failure.
Government Agency, Medical Society, and other Authoritative Publications:
|Websites for Additional Information|
The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.
|Reviewed||05/05/2016||Medical Policy & Technology Assessment Committee (MPTAC) review. Updated Discussion and References sections. Removed ICD-9 codes from Coding section.|
|Reviewed||05/07/2015||MPTAC review. Updated Description, Discussion, and References sections.|
|Revised||05/15/2014||MPTAC review. Revised criterion to include the Trofile DNA test. Updated the Description, Coding, Discussion, Definitions, References, Websites for Additional Information and Index sections.|
|Reviewed||05/09/2013||MPTAC review. Minor format changes. Updated Discussion, References, and Websites for Additional Information.|
|Reviewed||05/10/2012||MPTAC review. Updated Description, Discussion, Coding and References.|
|01/01/2012||Updated Coding section with 01/01/2012 CPT changes.|
|Revised||05/19/2011||MPTAC review. Revised criterion to clarify that HIV tropism testing is medically necessary in an individual prior to initiating a combination antiretroviral drug regimen with a coreceptor antagonist, and in an individual who has experienced virologic failure while receiving therapy that contains a CCR5 inhibitor. Removed not medically necessary statement for coreceptor tropism assay testing in the absence of antiretroviral treatment failure. Updated Discussion and References. Added Definitions and Websites for Additional Information.|
|Revised||05/13/2010||MPTAC review. Revised document title to Tropism Testing for HIV Management. Revised Clinical Indications, removing indications for phenotypic and genotypic assays used in HIV-1 management other than the coreceptor tropism assay test, Trofile™. Updated Discussion/General Information, Coding, References, and Index.|
|Revised||08/27/2009||MPTAC review. Revised/clarified medically necessary criteria for genotypic and phenotypic assays for drug resistance testing and for tropism testing with the coreceptor tropism assay based on DHHS guidelines. Clarified not medically necessary criterion for use of other coreceptor (genotypic) assay techniques. Updated Discussion and References.|
|Revised||05/21/2009||MPTAC review. Revisions as follows: 1) Subject/title to Phenotypic and Genotypic Assays in HIV Management; 2) Medically necessary criteria for HIV-treated individuals who have experienced virologic failure during antiretroviral therapy (ART), adding "defined as HIV RNA levels ≥500 but <1,000 copies/mL;" and criterion for testing pregnant women; 3) Revised not medically necessary criterion for individuals who have plasma HIV RNA levels of <500 copies/mL. Updated Discussion and References.|
|Revised||05/15/2008||MPTAC review. Revised/renamed document number to CG-LAB-03. Addition of medically necessary and not medically necessary criteria for HIV tropism testing with the coreceptor assay (Trofile™). Discussion, Coding, and References updated.|
|Revised||11/29/2007||MPTAC review. Addition of medically necessary criteria for HIV drug resistance testing through phenotype and genotype assays: In individuals with recently acquired HIV infection; and, in individuals with established HIV infection prior to initiating ART. Addition of timeframe criterion: HIV resistance testing is considered not medically necessary in individuals greater than four weeks after discontinuation of ART. Discussion and References updated.|
|Revised||12/07/2006||MPTAC review. Clarification of when concurrent genotypic and phenotypic assays are medically necessary. Concurrent genotypic and phenotypic testing is considered not medically necessary in all other situations. Coding updated; removed CPT 0023T deleted 12/31/2005.|
|Revised||09/14/2006||MPTAC review. Added concurrent testing by genotypic and phenotypic assay is duplicative. Updated References.|
|01/01/2006||Updated Coding section with 01/01/2006 CPT/HCPCS changes|
|11/22/2005||Added reference for Centers for Medicare and Medicaid Services (CMS) – National Coverage Determination (NCD).|
|Revised||09/22/2005||MPTAC review. Revision based on Pre-merger Anthem and Pre-merger WellPoint Harmonization.|
Last Review Date
|WellPoint Health Networks, Inc.|
|2.12.03||Phenotypic and Genotypic Resistance Assays in HIV Management|